Literature DB >> 9134206

Effects of sigma ligands on the nociceptin/orphanin FQ receptor co-expressed with the G-protein-activated K+ channel in Xenopus oocytes.

T Kobayashi1, K Ikeda, S Togashi, N Itoh, T Kumanishi.   

Abstract

Taking advantage of the functional coupling of the nociceptin/orphanin FQ receptor with the G-protein-activated inwardly rectifying K+ (GIRK) channel, we investigated the effects of various sigma ligands on the nociceptin/orphanin FQ receptor in Xenopus oocytes co-injected with the cloned nociceptin/orphanin FQ receptor and GIRK1 mRNAs. Carbetapentane and rimcazole, which induced no current response at 100 microM, reversibly suppressed the inward K+ current responses induced by nociceptin in a concentration-dependent manner, and the IC50 values (microM) for these compounds were 9.0 and 12.6, respectively. (+/-)-N-allylnormetazocine. (+)-cyclazocine, (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine and 1,3-di-(2-tolyl)guanidine, at 100 microM, had no effect on the receptor. These results suggest that carbetapentane and rimcazole act as antagonists at the nociceptin/orphanin FQ receptor and may be involved in pain regulation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134206      PMCID: PMC1564584          DOI: 10.1038/sj.bjp.0701068

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  6 in total

Review 1.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Further characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitro.

Authors:  S Werthwein; U Bauer; M Nakazi; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.

Authors:  G Calo'; R Guerrini; R Bigoni; A Rizzi; G Marzola; H Okawa; C Bianchi; D G Lambert; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

4.  Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.

Authors:  N Zaveri; W E Polgar; C M Olsen; A B Kelson; P Grundt; J W Lewis; L Toll
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

5.  UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.

Authors:  J McDonald; G Calo; R Guerrini; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-15       Impact factor: 3.000

Review 6.  Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.

Authors:  Nurulain Zaveri
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.